Varying Regulatory Philosophies and AD Approval Priorities, AD/PD™ Session Spotlight

In this episode of AD/PD™ Session Spotlight, we delve into Forum Discussion 1, "Varying Regulatory Philosophies and AD Approval Priorities – USA, EU, Asia, and Other Parts of the World," a dynamic exchange exploring how regional regulatory approaches impact the development, approval, and accessibility of Alzheimer’s disease therapies.Co-moderated by Agneta Nordberg (Sweden) and David Holtzman (USA), this discussion brings together insights from international regulatory and clinical experts: Naohiro Egawa (Japan), Tamara Shiner (Israel), Henrik Zetterberg (Sweden), and Pavel Balabanov (The Netherlands).Key highlights include:• The complex landscape of disease-modifying drug approvals, exemplified by the case of kinumab• Contrasts in regulatory frameworks between the EMA, FDA, and Japan’s PMDA• The evolving role of biomarkers in diagnosis and treatment selection• Ongoing challenges in balancing risk, clinical utility, and access across diverse healthcare systemsThis episode is a must-listen for global stakeholders in Alzheimer’s research, regulation, and clinical care, looking to navigate the nuances of regional policy and foster cross-border collaboration in advancing neurodegenerative disease treatments.This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.https://adpd.kenes.com/